Close Menu

NEW YORK – UK-based diagnostics firm Binding Site is developing a MALDI mass spectrometry-based test for plasma cell disorders using an approach licensed from the Mayo Clinic.

The company plans to launch a CE-IVD version of the test in 2021 and anticipates the launch of a US Food and Drug Administration-cleared test shortly thereafter, said Stephen Harding, Binding Site's chief scientific officer.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.